Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Post Traumatic Stress Disorder Clinical Trial

Official title:

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05948540
• Other study ID #: S-21-02 (Daridorexant)
• Status: Recruiting
• Phase: Phase 2
• Start date: November 2, 2023
• Est. completion date: September 2026

Study information

• Verified date: May 2024
• Source: U.S. Army Medical Research and Development Command
• Contact: Dr. Kimberly del Carmen
• Phone: Please reach out by email
• Email: kimberly.a.delcarmen.civ[@]health.mil
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.

Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD.

Please see NCT05422612 for information on the S-21-02 Master Protocol.

Description:

The general structure of this Adaptive Platform Trial (APT) consists of a 30-day Screening Period, a 12-week Platform Treatment Period, and a 4-week Safety Follow-up. The S-21-02 Platform Trial will evaluate the safety and efficacy of multiple investigational products for the treatment of PTSD (see NCT05422612 for Master Protocol information). Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control subjects, where all interventions may be compared to a common control (placebo). This record only includes information relevant to the daridorexant cohort.

Once a participant meets all eligibility criteria for the Master Protocol, eligibility for each currently enrolling intervention cohort is assessed. Eligible participants will be randomized with equal probability into a cohort. Participants randomized to the daridorexant cohort are then randomly assigned to receive either daridorexant or placebo in a ratio defined by the number of cohorts for which they are eligible, for the duration of the 12-week treatment period.

Parties interested in having their intervention considered for testing within the DOD PTSD APT should complete a request for information form using this webpage https://citeline.qualtrics.com/jfe/form/SV_0oDoJXvIL7EFM1M.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: September 2026
• Est. primary completion date: March 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT05422612).

Exclusion Criteria:

The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT05422612).

1. History of narcolepsy.

2. History of any treatment with daridorexant.

Related Conditions & MeSH terms

• Post Traumatic Stress Disorder
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Intervention

Drug:
• Intervention C Daridorexant
Daridorexant will be administered 50 mg once daily at least 2 hours after the last meal and within 30 minutes of going to bed.
• Intervention C Placebo
A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.

Locations

Country	Name	City	State
United States	Advanced Discovery Research	Atlanta	Georgia
United States	Homestead Associates in Research, Inc.	Miami	Florida

Sponsors (6)

Lead Sponsor	Collaborator
U.S. Army Medical Research and Development Command	Berry Consultants, Cambridge Cognition Ltd, Citeline, Idorsia Pharmaceuticals Ltd., PPD

Country where clinical trial is conducted

United States, 

References & Publications (1)

Viele K. Allocation in platform trials to maintain comparability across time and eligibility. Stat Med. 2023 Jul 20;42(16):2811-2818. doi: 10.1002/sim.9750. Epub 2023 Apr 23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit).	A change in PTSD symptom severity from baseline as measured by CAPS-5-R Past Month. The range of the scale is 0-200. The higher the score at baseline, the worse the PTSD severity. The larger the decrease in score from baseline, the better the outcome.	12 Weeks
Primary	Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.	The C-SSRS is an assessment of suicidal ideation and behavior in clinical and research settings. The C-SSRS consists of 16 questions that ask about suicidal ideation and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). This 5-item subscale ranges from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent).	12 Weeks
Secondary	Frequency of treatment-emergent adverse events (TEAEs).	The TEAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA.	12 Weeks
Secondary	Severity of treatment-emergent adverse events (TEAEs).	The TEAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA.	12 Weeks
Secondary	Frequency of serious adverse events (SAEs)	The SAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA	12 Weeks
Secondary	Severity of serious adverse events (SAEs).	The SAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA	12 Weeks
Secondary	Relative change from Baseline to Week 12 in CAPS-5-R, Past Month total score.	A relative change in PTSD symptom severity from baseline as measured by the Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R) Past Month. The range of the scale is 0-200. The higher the score at baseline, the worse the PTSD severity. The larger the decrease in score from baseline, the better the outcome.	12 Weeks
Secondary	Number of participants with a Response Rate =30%	=30% reduction from Baseline to 12 Weeks in the Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R), Past Month total score. The range of the scale is 0-200. The higher the score, the worse the PTSD severity. The larger the decrease in score from baseline, the better the outcome.	12 Weeks
Secondary	Number of participants with a Response Rate =50%	=50% reduction from Baseline to 12 Weeks in the Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R), Past Month total score. The range of the scale is 0-200. The higher the score, the worse the PTSD severity. The larger the decrease in score from baseline, the better the outcome.	12 Weeks
Secondary	Number of participants Achieving Remission.	Achieving remission: defined as the Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R), Past Month total score <18. The range of the scale is 0-200. The higher the score, the worse the PTSD severity.	12 Weeks